BY MIRABEL ODETA
The U.S. Supreme Court on Thursday temporarily protected nationwide access to the abortion pill mifepristone by allowing the medication to continue being prescribed through telemedicine appointments and delivered by mail while an ongoing legal battle continues. The decision keeps in place a 2023 federal regulation introduced during former President Joe Biden’s administration that expanded access to the medication and removed the requirement for patients to visit a clinic in person before receiving the drug.
The ruling came after two manufacturers of mifepristone, Danco Laboratories and GenBioPro, asked the nation’s highest court to intervene after a lower court moved to restrict access to the medication. The Supreme Court granted the companies’ request and paused the lower court ruling while the broader case proceeds through the legal system.
The order issued by the justices was unsigned and did not include a detailed explanation, which is common in emergency decisions. However, conservative Justices Samuel Alito and Clarence Thomas publicly dissented, signaling continued divisions within the court over abortion-related issues.
Earlier this month, the New Orleans-based 5th U.S. Circuit Court of Appeals ordered the reinstatement of an older federal rule requiring women seeking mifepristone to attend an in-person medical appointment before obtaining the medication. That decision threatened to sharply reduce access to medication abortion, particularly for women living in states with strict abortion laws or limited healthcare access.
Mifepristone, approved by the U.S. Food and Drug Administration in 2000, is commonly used as part of a two-drug regimen for terminating pregnancies within the first 10 weeks. It is typically followed by misoprostol and has become the most widely used abortion method in the United States. According to reproductive health experts, medication abortions now account for roughly two-thirds of all abortions nationwide.
The legal challenge was brought by Republican-led Louisiana, which argued that the FDA acted improperly when it eased restrictions on the drug in 2023. State officials claimed the rule change contributed to a rise in medication abortions despite Louisiana’s near-total abortion ban. The lawsuit also alleged that the FDA ignored potential health risks linked to the medication, including severe bleeding and infections.
Supporters of abortion rights viewed the Supreme Court’s decision as a major, though temporary, victory. Advocacy groups warned that allowing the lower court ruling to stand would have immediately disrupted abortion access across large parts of the country and created confusion for patients and healthcare providers.
Alexis McGill Johnson, president of Planned Parenthood Federation of America, described the ruling as an important relief for patients seeking reproductive healthcare. She emphasized that legal battles over abortion access are far from over and warned that conservative groups are expected to continue challenging abortion-related protections in courts across the country.
Lizzy Hinkley, legal director for the Abortion Coalition for Telemedicine, also welcomed the decision, arguing that efforts to restrict telemedicine abortions are designed to create barriers for women seeking healthcare. She said the case represents another attempt to limit reproductive rights through the courts following the Supreme Court’s controversial 2022 Dobbs decision.
The Dobbs ruling overturned the landmark 1973 Roe v. Wade decision, which had guaranteed a constitutional right to abortion nationwide for nearly five decades. Since that ruling, numerous Republican-led states have enacted strict abortion bans or severe restrictions, dramatically reshaping abortion access across the United States.
The current Supreme Court has a 6-3 conservative majority, and abortion remains one of the most politically divisive issues in the country. With congressional elections approaching, legal disputes involving abortion rights are expected to remain central in national political debates.
Justice Samuel Alito, in his dissent, argued that allowing abortion pills to be delivered by mail undermines states like Louisiana that have chosen to ban abortion. He criticized medical providers and organizations in states that support abortion rights for helping patients obtain medication across state lines.
Justice Clarence Thomas issued a separate dissent, arguing that the federal Comstock Act prohibits mailing drugs intended for abortion. He also sharply criticized the pharmaceutical companies involved in the case, claiming they should not receive emergency legal protection while profiting from abortion-related medication.
The manufacturers defended the safety and legality of mifepristone in court filings. Danco Laboratories noted that Mifeprex, the brand-name version of the drug, is its only product, while GenBioPro said the generic version accounts for most of its business revenue.
GenBioPro CEO Evan Masingill said the company remains committed to ensuring access to what he described as essential, evidence-based healthcare. Danco spokesperson Abby Long added that the court’s decision ensures Americans will continue to have access to a medication that has been proven safe and effective through decades of medical use and scientific study.
Medical organizations and reproductive health experts strongly support the continued availability of mifepristone. The FDA has repeatedly stated that the drug was approved using scientific evidence and remains safe when used as directed. Researchers have also pointed to hundreds of studies and clinical trials showing that serious complications linked to the medication are extremely rare.
Camille Clare, president of the American College of Obstetricians and Gynecologists, described mifepristone as one of the safest and most extensively studied medications currently available in the United States.
Opponents of abortion rights, however, criticized the Supreme Court’s decision. Carol Tobias, president of the anti-abortion organization National Right to Life, argued that women facing unexpected pregnancies deserve more direct medical support rather than what she called a “mail-order abortion system.”
The legal battle over mifepristone is far from over. In addition to Louisiana’s case, several other Republican-led states have launched lawsuits seeking even stricter limits on the abortion pill. Texas and Florida filed a separate lawsuit challenging the FDA’s original approval of mifepristone in 2000, as well as later policy changes that expanded access to the drug. Missouri, Kansas, and Idaho are also pursuing another case arguing that the FDA improperly loosened restrictions in 2016.
The Supreme Court had already temporarily paused the lower court’s restrictions twice earlier this month while considering how to proceed. Thursday’s decision now keeps access to telemedicine prescriptions and mail delivery available nationwide until the broader legal challenge is fully resolved.
For now, women in the United States can continue receiving mifepristone through virtual medical consultations and mail delivery, but the future of medication abortion remains uncertain as multiple court battles continue to move through the judicial system.
Original article
Comments